Quantcast

Contract Research Organization WCCT Global Announces Streamlined Clinical Patient Recruitment Process for Infectious Disease Drug Development

July 29, 2013

Clinical Patient Recruitment is now streamlined for infectious Disease Drug Development. This process uses many of today's cutting edge technologies to expedite the entire clinical research process.

Costa Mesa, CA (PRWEB) July 28, 2013

WCCT Global, a contract research organization headquartered in Southern California announces today the successful implementation of an innovative clinical patient recruitment strategy which will enable the acceleration of Infectious Disease Clinical Research. The rapid emergence of resistant bacterial, fungal and viral strains has weakened many of our existing anti-infective agents. New anti-infective targets have been discovered by academia and the Pharma Industry and regulatory agencies have implemented plans to expedite the review of clinical trials with these newly evolving anti-infective agents. WCCT Global has recognized the urgent need to expedite the protocol implementation and clinical patient recruitment elements of the clinical research programs such that timelines can be shortened by 25 to 30%. WCCT Global was able to implement this expedited process based upon its extensive experience in infectious disease clinical research. WCCT Global is currently managing projects in Chronic Hepatitis C, Chronic Hepatitis B, Complicated Skin and Skin Structure infections, Otitis Externa, Vaccines and Fungal Infections.

Jon Rojas, CSO, WCCT Global said, “We feel that this new paradigm for expedited clinical development in infectious disease is important because these new products that are in development represent the potential to fight infections that have been causing the deaths of thousands in the United States every year. The streamlined process that we have implemented will greatly increase the speed and precision of the research that is being performed to support the safety and efficacy of these new and novel agents. The sponsors that have taken part in this research with WCCT Global seem have greatly benefited from the experience.”

WCCT Global is a multi-site, full-service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting-edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you would like more information about WCCT Global’s Glaucoma capabilities, CLICK HERE.

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/7/prweb10969614.htm


Source: prweb



comments powered by Disqus